Genmab — Earnings Release 2013

Oct 23, 2013

Company Announcement

-- Worldwide net sales of Arzerra® in Q3 2013 totaled GBP 17.8 million
-- Genmab expects royalty payment of approx. DKK 31 million

Copenhagen, Denmark; October 23, 2013 – Genmab A/S (OMX: GEN) announced today
that the Arzerra (ofatumumab) net sales during the third quarter of 2013 were
GBP 17.8 million (approximately DKK 155 million). This figure consists of net
sales in the US of GBP 13.1 million and in the rest of the world of GBP 4.7
million. Under the terms of the collaboration with GlaxoSmithKline (GSK),
Genmab expects to receive a royalty payment of approximately DKK 31 million.

During the first half of 2013, rest of world sales of Arzerra were impacted by
sales related to the supply of Arzerra for clinical trials run by other
companies. Sales were not positively impacted by clinical trial material sales
during the third quarter.

The conversion from GBP to DKK has been made using the Danish Central Bank
average rates for the third quarter of 2013 (GBP 1.00 = DKK 8.7287).

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company’s first marketed
antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab’s validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab’s strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo(TM);
the DuoBody™ logo; HuMax®; HuMax-CD20®; DuoBody®, HexaBody(TM) and UniBody®.
Arzerra® is a registered trademark of GlaxoSmithKline.

Company Announcement no. 45
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark